StreetInsider.com News Articles

Form 10-K Atea Pharmaceuticals, For: Dec 31

Thu, 05 Mar 2026 16:51:00 -0500

si-local-file:///var/storage/secattach/20260305/26119927.html

Form 10-K Atea Pharmaceuticals, For: Dec 31

Thu, 05 Mar 2026 16:51:00 -0500

si-local-file:///var/storage/secattach/20260305/26119927.html

Form 8-K Atea Pharmaceuticals, For: Mar 05

Thu, 05 Mar 2026 16:11:00 -0500

si-local-file:///var/storage/secattach/20260305/26118993.html

Form 8-K Atea Pharmaceuticals, For: Mar 05

Thu, 05 Mar 2026 16:11:00 -0500

si-local-file:///var/storage/secattach/20260305/26118993.html

Aviragen Therapeutics (AVIR) Misses Q4 EPS by 13c

Thu, 05 Mar 2026 16:09:18 -0500

Aviragen Therapeutics (NASDAQ: AVIR) reported Q4 EPS of ($0.57), $0.13 worse than the analyst estimate of ($0.44).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Thu, 05 Mar 2026 16:05:00 -0500

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026

Presented Results Reinforcing Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Regimen for the Treatment of HCV at the 2025 EASL Congress and The Liver Meeting® 2025, the Annual Meeting of AASLD

Physician KOLs Underscored the Need for a New Optimized HCV Regimen to Address Treatment Paradigm Shifts, Including Test-and-Treat Model of Care

Expanded Antiviral Pipeline with New Hepatitis E

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Thu, 05 Mar 2026 16:05:00 -0500

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026

Presented Results Reinforcing Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Regimen for the Treatment of HCV at the 2025 EASL Congress and The Liver Meeting® 2025, the Annual Meeting of AASLD

Physician KOLs Underscored the Need for a New Optimized HCV Regimen to Address Treatment Paradigm Shifts, Including Test-and-Treat Model of Care

Expanded Antiviral Pipeline with New Hepatitis E

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Thu, 05 Mar 2026 16:05:00 -0500

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026

Presented Results Reinforcing Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Regimen for the Treatment of HCV at the 2025 EASL Congress and The Liver Meeting® 2025, the Annual Meeting of AASLD

Physician KOLs Underscored the Need for a New Optimized HCV Regimen to Address Treatment Paradigm Shifts, Including Test-and-Treat Model of Care

Expanded Antiviral Pipeline with New Hepatitis E

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Thu, 05 Mar 2026 16:05:00 -0500

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026

Presented Results Reinforcing Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Regimen for the Treatment of HCV at the 2025 EASL Congress and The Liver Meeting® 2025, the Annual Meeting of AASLD

Physician KOLs Underscored the Need for a New Optimized HCV Regimen to Address Treatment Paradigm Shifts, Including Test-and-Treat Model of Care

Expanded Antiviral Pipeline with New Hepatitis E

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Thu, 05 Mar 2026 16:05:00 -0500

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026

Presented Results Reinforcing Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Regimen for the Treatment of HCV at the 2025 EASL Congress and The Liver Meeting® 2025, the Annual Meeting of AASLD

Physician KOLs Underscored the Need for a New Optimized HCV Regimen to Address Treatment Paradigm Shifts, Including Test-and-Treat Model of Care

Expanded Antiviral Pipeline with New Hepatitis E

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Thu, 05 Mar 2026 16:05:00 -0500

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026

Presented Results Reinforcing Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Regimen for the Treatment of HCV at the 2025 EASL Congress and The Liver Meeting® 2025, the Annual Meeting of AASLD

Physician KOLs Underscored the Need for a New Optimized HCV Regimen to Address Treatment Paradigm Shifts, Including Test-and-Treat Model of Care

Expanded Antiviral Pipeline with New Hepatitis E

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Thu, 05 Mar 2026 16:05:00 -0500

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026

Presented Results Reinforcing Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Regimen for the Treatment of HCV at the 2025 EASL Congress and The Liver Meeting® 2025, the Annual Meeting of AASLD

Physician KOLs Underscored the Need for a New Optimized HCV Regimen to Address Treatment Paradigm Shifts, Including Test-and-Treat Model of Care

Expanded Antiviral Pipeline with New Hepatitis E

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Thu, 05 Mar 2026 16:05:00 -0500

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026

Presented Results Reinforcing Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Regimen for the Treatment of HCV at the 2025 EASL Congress and The Liver Meeting® 2025, the Annual Meeting of AASLD

Physician KOLs Underscored the Need for a New Optimized HCV Regimen to Address Treatment Paradigm Shifts, Including Test-and-Treat Model of Care

Expanded Antiviral Pipeline with New Hepatitis E

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Thu, 05 Mar 2026 16:05:00 -0500

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026

Presented Results Reinforcing Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Regimen for the Treatment of HCV at the 2025 EASL Congress and The Liver Meeting® 2025, the Annual Meeting of AASLD

Physician KOLs Underscored the Need for a New Optimized HCV Regimen to Address Treatment Paradigm Shifts, Including Test-and-Treat Model of Care

Expanded Antiviral Pipeline with New Hepatitis E

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Thu, 05 Mar 2026 16:05:00 -0500

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026

Presented Results Reinforcing Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Regimen for the Treatment of HCV at the 2025 EASL Congress and The Liver Meeting® 2025, the Annual Meeting of AASLD

Physician KOLs Underscored the Need for a New Optimized HCV Regimen to Address Treatment Paradigm Shifts, Including Test-and-Treat Model of Care

Expanded Antiviral Pipeline with New Hepatitis E

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Thu, 05 Mar 2026 16:05:00 -0500

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026

Presented Results Reinforcing Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Regimen for the Treatment of HCV at the 2025 EASL Congress and The Liver Meeting® 2025, the Annual Meeting of AASLD

Physician KOLs Underscored the Need for a New Optimized HCV Regimen to Address Treatment Paradigm Shifts, Including Test-and-Treat Model of Care

Expanded Antiviral Pipeline with New Hepatitis E

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Thu, 05 Mar 2026 16:05:00 -0500

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026

Presented Results Reinforcing Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Regimen for the Treatment of HCV at the 2025 EASL Congress and The Liver Meeting® 2025, the Annual Meeting of AASLD

Physician KOLs Underscored the Need for a New Optimized HCV Regimen to Address Treatment Paradigm Shifts, Including Test-and-Treat Model of Care

Expanded Antiviral Pipeline with New Hepatitis E

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026

Thu, 26 Feb 2026 07:00:00 -0500

BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, March 5, 2026, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2025, and to provide a business update.

To access the live conference call, participants may register here. The live audio webcast of

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026

Thu, 26 Feb 2026 07:00:00 -0500

BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, March 5, 2026, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2025, and to provide a business update.

To access the live conference call, participants may register here. The live audio webcast of

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026

Thu, 26 Feb 2026 07:00:00 -0500

BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, March 5, 2026, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2025, and to provide a business update.

To access the live conference call, participants may register here. The live audio webcast of

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026

Thu, 26 Feb 2026 07:00:00 -0500

BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, March 5, 2026, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2025, and to provide a business update.

To access the live conference call, participants may register here. The live audio webcast of

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

Tue, 24 Feb 2026 07:00:00 -0500

Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus

Initiation of Phase 1 Clinical Program Anticipated Mid-2026

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced in vitro results showing that two proprietary oral nucleotide analogs, AT-587 and AT-2490, exhibit promising antiviral profiles as potential first-in-class inhibitors for the treatment of Hepatitis E virus (HEV) infection, a positive-sense, single-stranded RNA virus that primarily

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

Tue, 24 Feb 2026 07:00:00 -0500

Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus

Initiation of Phase 1 Clinical Program Anticipated Mid-2026

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced in vitro results showing that two proprietary oral nucleotide analogs, AT-587 and AT-2490, exhibit promising antiviral profiles as potential first-in-class inhibitors for the treatment of Hepatitis E virus (HEV) infection, a positive-sense, single-stranded RNA virus that primarily

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

Tue, 24 Feb 2026 07:00:00 -0500

Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus

Initiation of Phase 1 Clinical Program Anticipated Mid-2026

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced in vitro results showing that two proprietary oral nucleotide analogs, AT-587 and AT-2490, exhibit promising antiviral profiles as potential first-in-class inhibitors for the treatment of Hepatitis E virus (HEV) infection, a positive-sense, single-stranded RNA virus that primarily

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

Tue, 24 Feb 2026 07:00:00 -0500

Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus

Initiation of Phase 1 Clinical Program Anticipated Mid-2026

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced in vitro results showing that two proprietary oral nucleotide analogs, AT-587 and AT-2490, exhibit promising antiviral profiles as potential first-in-class inhibitors for the treatment of Hepatitis E virus (HEV) infection, a positive-sense, single-stranded RNA virus that primarily